Search results
Results from the WOW.Com Content Network
It was established in 2013 and is published exclusively online by Cell Press. It is the official journal of the International Society for Stem Cell Research. The editor-in-chief is Martin Pera (Jackson Laboratory). According to the Journal Citation Reports, the journal has a 2020 impact factor of 7.765. [1]
He is one of the founders of the field of liquid biopsy for cancer detection and evaluation and published the first study on the US on disseminated tumor cells (DTC) focusing on patients with early stage breast cancer, [17] and followed this up with a study showing that such cells identify patients at increased risk for metastasis. [18]
The 2016 Guidelines for Stem Cell Research and Clinical Translation Archived 2019-02-04 at the Wayback Machine have been adopted by researchers, clinicians, organizations, and institutions around the world. In 2013, the Society's official journal, Stem Cell Reports, was established; it is published monthly by Cell Press on the Society's behalf. [7]
The cancer stem cell model, also known as the Hierarchical Model proposes that tumors are hierarchically organized (CSCs lying at the apex [6] (Fig. 3).) Within the cancer population of the tumors there are cancer stem cells (CSC) that are tumorigenic cells and are biologically distinct from other subpopulations [7] They have two defining features: their long-term ability to self-renew and ...
It covers contemporary and emerging areas in stem cells, including embryonic and adult stem cells, and related lineage and cloning issues. The journal also publishes reviews covering basic, clinical, biotechnology, regulatory, and ethical aspects of stem cell research and applications. [1] The journal got its current name in 2009 from Stem Cell ...
Costs of stem cell therapies range widely by clinic, condition, and cell type, but most commonly range between $10,000-$20,000. [108] Insurance does not cover stem cell injections at clinics so patients often use on-line fundraising. [109]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Andrew Louis Pecora (born 1957) is an American hematologist and oncologist involved in research on the use of stem cells and oncolytic viruses to treat diseases, including cancer. [1] He is the CEO of Outcomes Matter Innovations.